KMT2A and acute myeloid leukemia: Moreover, Nos3 inactivation cooperated with AraC treatment to reduce leukemic engraftment in both MLL-AF9 and MLL-ENL models (Figure 6A) and reduced the vascular leakiness in the BM of AML-engrafted mice (Figure 6B).